Willow Biosciences Inc. (OTCQB: CANSF) (TSX:WLLW) released its financial and operating results for the three months ended March 31, 2023, revealing revenue of CA$274,000 ($203,000) compared to no revenue in Q1 2022. The company is in the development stage and expects to operate at a loss and use cash in operating activities as it conducts research and development on its biosynthesis pathways.
"The first quarter of this year marked significant progress against our stated goals to foster diversified commercial growth within our portfolio, and create opportunities for near-term revenue generation for the business all while experiencing reduced cash burn", stated Chris Savile, Willow's president and CEO. "We are on a solid trajectory in successfully executing on projects underway while pursuing new agreements, and our legacy yeast strain engineering capabilities along with …